Inclusion Criteria:

- adult patients at least 18 years of age with moderate to severe active RA for at
least 6 months;

- inadequate response to current anti-rheumatic therapies, including MTX;

- inadequate response or intolerance to treatment with 1 or more anti-TNF therapies
within 1 year of entering study;

- on stable MTX for at least 8 weeks before entering study;

- patients of reproductive potential must be using reliable methods of contraception.

Exclusion Criteria:

- major surgery (including joint surgery) within 8 weeks before screening, or planned
major surgery within 6 months after entering study;

- women who are pregnant or breast-feeding.